Different methods for measuring endogenous digitalis-like factor(s).
It is well recognized that one of the difficulties in the search for endogenous ligand(s) with digitalis-like properties (endogenous digitalis-like factor(s), EDLF) in mammals has been the lack of a unique, specific method for the accurate measurement of EDLF. Using C18 solid-phase extracts of plasma from normal adults and various patient groups, and purified extracts from umbilical cord plasma by affinity resin chromatography and HPLC, different methods to measure EDLF were evaluated. These were: (a) a human placenta radioreceptor assay (RRA) developed on the premise that competition for cardiac glycoside receptors was an absolute requirement for EDLF; (b) the inhibition of 86Rb uptake in human erythrocytes to estimate the potassium transport by the sodium pump; (c) an enzyme immunoassay specific for ouabain recently introduced in the market (DuPont Ouabain EIA Reagent Pack). The human placenta RRA was found to have the same ease of application as immunoassay, but could have major advantages in detecting active molecules, being "biologically more meaningful". Ouabain immunoreactivity correlated with EDLF values obtained by RRA, but in some instances the two assays were completely unrelated. Moreover, the high specificity of the DuPont antibody for ouabain (< 3% cross reactivity with digoxin) could be disadvantageous to detect EDLF not strictly resembling ouabain. The 86Rb uptake inhibition method correlated with RRA for EDLF purified by HPLC. It tested the complete enzymatic cycle and could therefore better reflect the in-vivo inhibitory activity of EDLF. However, it appeared not suitable for the routine EDLF evaluation in clinical studies since it was susceptible to sample osmolarity and required daily isolation of human erythrocytes possibly from the same donor. Results of the present study demonstrate that every assay has its limitations, and would suggest the use of multiple assays for EDLF detection.
Paci
A
A
Istituto di Fisiologia Clinica C.N.R., Pisa, Italy.
Balzan
S
S
Ledda
A
A
Ghoine
S
S
D002298:Cardenolides; D002316:Cardiotonic Agents / Q000097:blood*; D002851:Chromatography, High Pressure Liquid; D004077:Digoxin; D004912:Erythrocytes / Q000378:metabolism; D005260:Female; D005312:Fetal Blood / Q000378:metabolism; D006801:Humans; D007124:Immunoenzyme Techniques; D010920:Placenta / Q000378:metabolism; D011247:Pregnancy; D011869:Radioligand Assay; D012414:Rubidium Radioisotopes / Q000097:blood; D012503:Saponins / Q000097:blood*
D002298:Cardenolides; D002316:Cardiotonic Agents; D012414:Rubidium Radioisotopes; D012503:Saponins; C034504:digoxin-like factors; D004077:Digoxin